Clinical Trials
FDA agrees to clinical development plans for ISA247
Published in Medical Letter on the CDC and FDA, March 28th, 2004
The single-ascending-dose study involving approximately 46 subjects will be completed over a 6-week period by MDS Pharma Services in Phoenix, Arizona. Dosing was scheduled to commence on March 9th, 2004. This study will be used as the foundation to determine dosing of trans-ISA247 in future clinical trials for both psoriasis and renal transplantation.
"Based on analysis of previously collected data, trans-ISA247 is more bioavailable and therefore we expect to administer the drug at a lower dose...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Malaria
Plasmodium reichenowi reticulocyte binding-like genes exhibit rapid evolution - Tick-borne Encephalitis Vaccine
Progress reported in developing vaccine against tick-borne encephalitis - Adenovirus
Rapid quantitative diagnostic test for adenovirus type 4 evaluated - HIV/AIDS Pathogenesis
T-cell subsets harboring HIV in vivo have implications for HIV pathogenesis - Schistosomiasis
IL-13 receptor alpha 2 prolongs host survival in schistosomiasis - Acute Otitis Media
Docs mull antibiotics for ear infections - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
